Home > Insider Trading > Filing (0001022079-16-000229)

Filing Details

Accession Number:: 0001022079-16-000229
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-03-03 16:21:42
Reporting Period:: 2016-03-01

Filing Date:: 2016-03-03
Accepted Time:: 2016-03-03 16:21:42
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1022079	Quest Diagnostics Inc	DGX	Services-Medical Laboratories (8071)	161387862

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1222679	E Michael Prevoznik	C/O Quest Diagnostics Incorporated 3 Giralda Farms Madison NJ 07940	Svp & General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-03-01	1,994	$67.01	47,317	No	4	A	Direct
Common Stock	Disposition	2016-03-01	685	$67.01	46,632	No	4	F	Direct
Common Stock	Disposition	2016-03-01	919	$66.51	45,713	No	4	F	Direct
Common Stock	Disposition	2016-03-01	3,532	$68.19	42,181	No	4	S	Direct
Common Stock	Disposition	2016-03-01	283	$68.62	41,905	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	F	Direct
No	4	F	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	4,775	Indirect	401K

Footnotes

Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 25, 2013, approved in accordance with the requirements of Rule 16b-3(d).
Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award.
Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares.
The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 8, 2014.
This transaction was executed in multiple trades at prices ranging from $67.57 to $68.5415. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $68.6200 to $68.6207. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4.
These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.